ArticleNutrition & diabetes2026
Fibrillin-1 alleviates high glucose-induced fibroblast apoptosis and inflammation via autophagy activation.
Article in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective management of fibroblast inflammation and apoptosis caused by high glucose is pivotal for mitigating diabetic foot ulcers (DFUs). Recent studies have indicated the potential involvement of Fibrillin-1 (FBN1) in DFU healing through its impact on fibroblast proliferation, migration, and apoptosis. However, detailed cellular mechanism remained uncleared.
methodsThree primary fibroblast cultures were established conventionally. The impact of FBN1 was studied through knockdown and overexpression. FBN1 levels were gauged via reverse transcription-quantitative polymerase chain reaction (RT-qPCR for mRNA) and Western blot (for protein). Immunofluorescence localized FBN1. Proliferation was assessed via MTT assays, and EDU staining tracked cell viability. TUNEL detected apoptosis. Inflammation was measured by ELISA. Electron microscopy visualized cellular structure changes linked to autophagy, corroborated by Western blot markers.
resultsFibroblasts exposed to high glucose exhibited dysregulated FBN1 expression and disrupted autophagy. FBN1 overexpression promoted proliferation and suppressed inflammation and apoptosis under high glucose conditions. Additionally, FBN1 was found to restore autophagy inhibited by high glucose. In contrast, FBN1 silencing further suppressed autophagy, thereby aggravating inflammation and apoptosis.
conclusionDysregulation of FBN1 in fibroblasts induced by high glucose hampers autophagy, ultimately leading to apoptosis and inflammation. The upregulation of FBN1 counters these processes, potentially enhancing the healing of DFUs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.